Close Menu

This article has been updated with information from Thermo Fisher's earnings call.

NEW YORK  – Thermo Fisher Scientific reported on Wednesday morning a 36 percent year-over-year rise in third quarter revenues, driven by COVID-19-related sales.

"We further accelerated our exceptional growth momentum in the third quarter," said Marc Casper, the firm's president, chairman, and CEO, in a statement. "Our teams executed very well to build our leadership in supporting the global pandemic response and also capture opportunities to grow our base business."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.